Article

Efficacy and Safety of targeted therapy Inhibitors for RET-driven Solid Cancer: A Systematic Review and Meta-analysis

2022-11-29

Abstract excerpt

Advanced and metastatic RET-driven solid cancer is not susceptible to chemotherapy or radiotherapy. The development of targeted therapy has led to a new therapeutic model. Nevertheless, no systematic evaluation of their efficacy and safety has been carried out in RET-driven solid cancer. Systematic review and single-arm meta-analysis were performed. Four electronic databases were searched (PubMed, Embase, Cochrane...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: e2ee0bd2-2d91-54bc-b063-e287498e85a3
DOI: 10.22541/au.166971966.65533901/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Efficacy and Safety of targeted therapy Inhibitors for RET-driven Solid Cancer: A Systematic Review and Meta-analysisDOI 10.22541/au.166971966.65533901/v1Read

[Expert consensus on BRAF inhibitors in the treatment of malignant solid tumors (2024 edition)].Semantic proximity Read

Clinical and Translational Challenges in Thyroid Cancer.Semantic proximity Read

RET aberrant cancers and RET inhibitor therapies: Current state-of-the-art and future perspectivesSemantic proximity Read

Targeted therapy in thyroid cancer: molecular alterations and clinical management.Semantic proximity Read

First report: PLATFORM study for precision treatment of rare tumors in China.Semantic proximity Read

Targeting RET alterations in cancer: Recent progress and future directions.Semantic proximity Read

State-of-the-Art Strategies for Targeting RET -Dependent CancersSemantic proximity Read

FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers with RET Gene Mutations or Fusions.Semantic proximity Read

BRAF-targeted therapy in non-melanomatous BRAF-mutant tumours: a systematic review of broad but histology-modulated efficacy.Semantic proximity Read

Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven OncologySemantic proximity Read

Precision Targeted Therapy with BLU-667 for RET-Driven Cancers.Semantic proximity Read

RET kinase inhibitors for the treatment of RET-altered thyroid cancers: Current knowledge and future directions.Semantic proximity Read